COMPASS Pathways plc CMPS PHARMA
Company Overview
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +227.27% |
| 6 Months: | +104.66% |
| 3 Months: | +19.69% |
| 1 Month: | +3.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.28 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CMPS COMPASS Pathways plc PHARMA | 14.04 | -3.70 | $1.94B | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -13.60M | -19.53M | -21.77M | -25.42M | -27.26M | -25.54M | -31.79M | -32.66M | -34.06M | -38.57M | -43.32M | -47.90M | -49.62M | -42.93M | -40.54M | -42.90M | -52.37M |
| Net Income | -17.53M | -15.85M | -12.71M | -17.53M | -15.85M | -21.17M | -21.04M | -18.37M | -24.21M | -28.34M | -33.39M | -35.19M | -38.10M | -38.50M | -17.86M | -38.40M | -137.72M | 91.20M | -253.79M |
| Diluted EPS | -0.44 | -0.38 | -0.35 | -0.44 | -0.38 | -0.50 | -0.50 | -0.43 | -0.57 | -620.00 | -0.67 | -0.55 | -0.56 | -0.56 | -0.24 | -0.41 | -1.44 | -0.30 | -1.88 |
| R&D Expense | - | - | 6.88M | 11.35M | 12.20M | 15.36M | 15.92M | 13.98M | 19.04M | 19.82M | 21.53M | 24.90M | 29.07M | 32.93M | 30.88M | 30.32M | 27.32M | 26.48M | 29.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -21.18M | -51.39M | -83.22M | -110.40M | -136.92M | -178.21M | -179.04M |
| Net Income | -19.61M | -60.33M | -71.74M | -91.50M | -118.46M | -155.12M | -287.86M |
| Diluted EPS | -2.62 | -3.55 | -1.79 | -2.16 | -2.32 | -2.30 | -3.08 |
| R&D Expense | 12.56M | 23.37M | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 203.46M | 300.90M | 197.29M | 275.99M | 213.67M | 210.35M |
| Total Equity | -14.37M | -30.39M | 196.56M | 284.41M | 181.28M | 225.74M | 154.69M | -52.85M |
| Cash & Equivalents | - | 24.97M | 190.33M | 273.24M | 143.21M | 220.20M | 165.08M | 149.61M |
| Long Term Debt | - | - | - | - | 0 | 28.76M | 24.65M | 14.11M |
| Total Liabilities | - | - | 6.89M | 16.49M | 16.01M | 50.24M | 58.97M | 263.20M |
| Current Liabilities | - | - | 6.89M | 15.11M | 15.60M | 19.60M | 34.02M | 247.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.81M | -41.38M | -67.75M | -105.45M | -97.38M | -119.19M | -157.24M |
| Investing Cash Flow | -165.00K | -628.00K | -334.00K | -596.00K | -64.00K | 0 | - |
| Financing Cash Flow | 18.38M | 194.16M | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Capital Expenditure | -165.00K | -131.00K | -334.00K | -596.00K | -66.00K | -0 | - |
| Free Cash Flow | -17.98M | -41.51M | -68.08M | -106.05M | -97.44M | -119.19M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 64.5% | -30.7% | -25.2% | -50.5% | -52.5% | -100.3% | 544.7% |
| ROCE % | - | -26.1% | -29.1% | -60.8% | -53.4% | -99.2% | 478.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 8.78% | 12.16M | $184.73M |
| 2 | RTW Investments LP | 7.73% | 10.70M | $162.55M |
| 3 | BIT Capital GmbH | 4.58% | 6.35M | $96.44M |
| 4 | Tang Capital Management, LLC | 3.61% | 5.00M | $75.95M |
| 5 | Two Sigma Investments, LP | 3.23% | 4.47M | $67.91M |
| 6 | Marshall Wace LLP | 3.13% | 4.33M | $65.75M |
| 7 | ARK Investment Management, LLC | 2.49% | 3.45M | $52.44M |
| 8 | Point72 Asset Management, L.P. | 1.89% | 2.62M | $39.81M |
| 9 | Logos Global Management LP | 1.62% | 2.25M | $34.18M |
| 10 | Eagle Health Investments Lp | 1.49% | 2.06M | $31.30M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CMPS
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQY09vTlV0UVRrbzU4VUkwUG9vOXZERkZVSVp4TVM5MXNnUVpoYUdQRlJiTnZkSmdFaEE5a1g2b0xlMFJYZXhCM2RuZ2tfZ2cyYmlRRnFtWWt3TGF2aGdWU2N3RTZ0MFhoMWNucE9RcjIxWk9jRDI3ZFY4dTFyRWpJREQtWllXQ0E0ZnRNTm…
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNV0p5Z0w2Sk5oUlQwaWRMTGhtVzdXMHdXMkVYdk1wYzNjOE9JN1paa05aYm5YcnpEVGFkSUk5WUdwLV9EVDNWSm9vYXBicXE5YzdlZ3piYThYYmppX001LUZlcWN2bTVjNHViVnQ0NmhWMEN2YW9kUFJHVjJOUnpUMU81ZU5BM3JJbEYxTF…
CMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filing - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNMjFhaEsxVWwtTjBVbGVhN3pQdjFoUjNzbEVmcVRraWUxb096N0R5YkpnSnlLcVFqMVRoaXQ1UWkxRHoyemd5RHgxS0RWQlN3MUduR25LSml3Ym4wamVRSkcxRnVxWlNOeGVDWHRrOG8tX2FrRldPckNNazR3MUhlc2NYbHhqdTA4dEdJUE…
(CMPS) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSURsZXRxQjJXVHR6N2Y2RlRrYkszb1BXbkJEQjdKSUxocHU0WnVkcTJBWU5jMGIzbE5lMjNxT3hPdTQtV3U1S0QzTVhVeFRkYVUyd2RRQWxtQTJUNFFuSFQ1cDQ1TEQtMDBpU2FKTWs2WEQ0aFhVUmx4bGE0TUg1Sl9EY3Y5OTdlTHAzbj…
Compass Pathways: Still A Buy, But The Exit Just Got Complicated (NASDAQ:CMPS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOUzR2YXJ2Tk5DeGZnS1c1LU5rQVpBSmZQaFduYTZ1V2x4SlpPaXdfZ1YwSjVDQ1Yxd21LN3FESmJYbWFHTkxkc184QlN1YWRLSlppTmFlaDlKVE1fRGhGYVBMU1lSbkhWanc0a3A4VmRmYUU5NGtab01IV1BTYTdIQThaZzQ1WllPS3ptM2…
Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxON3BoZXYtVloyYXVJMHA0amx2TFNJT2JXVU9FS1pIQThER0lqZXFIS0htMTFGUFp5eHc1alc4ZVowOXZLU09hMVNfOUJkajRzWlhud1hZX2dveHJWaEJQSVluXzZBYzhTbXo0SUpTdlZadUdieHdxdTY0TlR4NEhab2NIVVI0cFRlS1ZfLV…
CMPS — Frequently Asked Questions
What is the current share price of COMPASS Pathways plc (CMPS)?
As of 2026-09-19 21:16 PDT, COMPASS Pathways plc (CMPS) trades at $14.04 on NasdaqGS. Its 52-week range is $4.08 to $15.07.
What is the market capitalisation of CMPS?
COMPASS Pathways plc (CMPS) has a market capitalisation of $1.94B on NasdaqGS.
What is the P/E ratio of CMPS?
CMPS trades at a trailing price-to-earnings (P/E) ratio of -3.70. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 24.35.
Is CMPS a good stock to buy?
This page provides a data-driven analysis of COMPASS Pathways plc (CMPS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.